Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy

Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular physiology Vol. 235; no. 4; pp. 3142 - 3156
Main Authors Derakhshani, Afshin, Rezaei, Zohreh, Safarpour, Hossein, Sabri, Morteza, Mir, Atefeh, Sanati, Mohammad Amin, Vahidian, Fatemeh, Gholamiyan Moghadam, Ali, Aghadoukht, Ali, Hajiasgharzadeh, Khalil, Baradaran, Behzad
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.04.2020
Subjects
Antineoplastic Agents - pharmacology
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Combination therapy
drug resistance
Drug Resistance, Neoplasm - drug effects
Epidermal growth factor
ErbB-2 protein
Growth factors
HER2 positive
Humans
Immunotherapy
Lapatinib - therapeutic use
Monoclonal antibodies
Receptor, ErbB-2 - drug effects
Targeted cancer therapy
Trastuzumab
Trastuzumab - therapeutic use
trastuzumab
HER2 positive
breast cancer
drug resistance
Online AccessGet full text

Cover

Abstract Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has challenged the use of this drug in the management of HER2‐positive BC. Therefore, the determination of resistance mechanisms and the incorporation of new agents may lead to the development of a better blockade of the HER family receptor signaling. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab‐resistant HER2‐positive BC that have more effective influences in the management of this condition. In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab‐resistant HER2‐positive BC subjects. Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab‐resistant HER2‐positive BC that have more effective influences in the management of this condition. So, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab‐resistant HER2‐positive BC subjects.
AbstractList Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has challenged the use of this drug in the management of HER2‐positive BC. Therefore, the determination of resistance mechanisms and the incorporation of new agents may lead to the development of a better blockade of the HER family receptor signaling. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab‐resistant HER2‐positive BC that have more effective influences in the management of this condition. In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab‐resistant HER2‐positive BC subjects.
Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has challenged the use of this drug in the management of HER2‐positive BC. Therefore, the determination of resistance mechanisms and the incorporation of new agents may lead to the development of a better blockade of the HER family receptor signaling. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab‐resistant HER2‐positive BC that have more effective influences in the management of this condition. In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab‐resistant HER2‐positive BC subjects. Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab‐resistant HER2‐positive BC that have more effective influences in the management of this condition. So, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab‐resistant HER2‐positive BC subjects.
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) comprises around 20-30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has challenged the use of this drug in the management of HER2-positive BC. Therefore, the determination of resistance mechanisms and the incorporation of new agents may lead to the development of a better blockade of the HER family receptor signaling. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab-resistant HER2-positive BC that have more effective influences in the management of this condition. In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab-resistant HER2-positive BC subjects.Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) comprises around 20-30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has challenged the use of this drug in the management of HER2-positive BC. Therefore, the determination of resistance mechanisms and the incorporation of new agents may lead to the development of a better blockade of the HER family receptor signaling. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab-resistant HER2-positive BC that have more effective influences in the management of this condition. In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab-resistant HER2-positive BC subjects.
Author Rezaei, Zohreh
Vahidian, Fatemeh
Safarpour, Hossein
Aghadoukht, Ali
Hajiasgharzadeh, Khalil
Mir, Atefeh
Baradaran, Behzad
Derakhshani, Afshin
Sabri, Morteza
Sanati, Mohammad Amin
Gholamiyan Moghadam, Ali
Author_xml – sequence: 1
  givenname: Afshin
  orcidid: 0000-0002-3243-233X
  surname: Derakhshani
  fullname: Derakhshani, Afshin
  organization: Tabriz University of Medical Sciences
– sequence: 2
  givenname: Zohreh
  surname: Rezaei
  fullname: Rezaei, Zohreh
  email: z.rezaei222@pgs.usb.ac.ir
  organization: University of Sistan and Balouchestan
– sequence: 3
  givenname: Hossein
  surname: Safarpour
  fullname: Safarpour, Hossein
  organization: Birjand University of Medical Sciences
– sequence: 4
  givenname: Morteza
  surname: Sabri
  fullname: Sabri, Morteza
  organization: University of Sistan and Balouchestan
– sequence: 5
  givenname: Atefeh
  surname: Mir
  fullname: Mir, Atefeh
  organization: University of Sistan and Balouchestan
– sequence: 6
  givenname: Mohammad Amin
  surname: Sanati
  fullname: Sanati, Mohammad Amin
  organization: Birjand University of Medical Sciences
– sequence: 7
  givenname: Fatemeh
  surname: Vahidian
  fullname: Vahidian, Fatemeh
  organization: Tabriz University of Medical Sciences
– sequence: 8
  givenname: Ali
  surname: Gholamiyan Moghadam
  fullname: Gholamiyan Moghadam, Ali
  organization: University of Damghan
– sequence: 9
  givenname: Ali
  surname: Aghadoukht
  fullname: Aghadoukht, Ali
  organization: University of Kurdistan
– sequence: 10
  givenname: Khalil
  surname: Hajiasgharzadeh
  fullname: Hajiasgharzadeh, Khalil
  organization: Tabriz University of Medical Sciences
– sequence: 11
  givenname: Behzad
  orcidid: 0000-0002-8642-6795
  surname: Baradaran
  fullname: Baradaran, Behzad
  email: baradaranb@tbzmed.ac.ir
  organization: Tabriz University of Medical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31566722$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1K9DAYhYMoOv4svAEpuNFFNT9N2ixl8BdBEd0JIU3f0QxtWpNWGVdewneN35WYcdSFoKu8cJ5zCOeso2XXOkBom-ADgjE9nJrugEpKxBIaESzzNBOcLqNR1EgqeUbW0HoIU4yxlIytojVGuBA5pSN0f_UM3rSNdQ9J73Xoh9eh0WXiIdjQa2cgsS45O76h_9_-dW2wvX2GpPQQ0cTMdZ8MYe6OIaV1uretS_pH8LqbbaKVia4DbH2-G-ju5Ph2fJZeXp2ej48uU5MRKVJWFZkWjGrAE0kkLowUuqoAQ7xkIbhhWVRzQ8uSlJxCxc2kYCIXEkTJJdtAe4vczrdPA4ReNTYYqGvtoB2ColTKjOe4mKO7P9BpO3gXf6coY4wLhgmO1M4nNZQNVKrzttF-pr56i8D-AjC-DcHD5BshWM03UXET9bFJZA9_sMb2Hz3Fwm39l-PF1jD7PVpdjK8XjndDSZ2q
CitedBy_id crossref_primary_10_3390_cancers12041047
crossref_primary_10_3390_cancers14225678
crossref_primary_10_3390_cancers13194797
crossref_primary_10_1016_j_celrep_2021_110160
crossref_primary_10_1186_s12920_023_01762_x
crossref_primary_10_30895_2221_996X_2025_552
crossref_primary_10_1021_acs_molpharmaceut_2c00503
crossref_primary_10_3390_biom14020158
crossref_primary_10_2147_CMAR_S334680
crossref_primary_10_1002_smll_202303934
crossref_primary_10_3389_fgene_2023_1184600
crossref_primary_10_1016_j_cbi_2022_110108
crossref_primary_10_1038_s41573_022_00579_0
crossref_primary_10_1620_tjem_2024_J026
crossref_primary_10_3389_fonc_2023_1286392
crossref_primary_10_1080_08923973_2023_2183352
crossref_primary_10_1016_j_cyto_2020_155213
crossref_primary_10_1186_s40364_023_00453_0
crossref_primary_10_1016_j_pharmthera_2023_108417
crossref_primary_10_1186_s43556_024_00239_2
crossref_primary_10_3390_cancers13246352
crossref_primary_10_1186_s12885_024_12478_1
crossref_primary_10_3390_curroncol29090476
crossref_primary_10_1007_s12272_024_01494_1
crossref_primary_10_7759_cureus_78471
crossref_primary_10_1016_j_intimp_2024_111549
crossref_primary_10_3389_fsurg_2022_862617
crossref_primary_10_1007_s12032_021_01556_0
crossref_primary_10_1016_j_humimm_2024_111221
crossref_primary_10_1111_cas_16008
crossref_primary_10_1016_j_taap_2023_116652
crossref_primary_10_3390_cancers12061540
crossref_primary_10_1016_j_csbj_2021_07_030
crossref_primary_10_3390_cancers15071987
crossref_primary_10_1007_s13346_021_01041_1
crossref_primary_10_1038_s41388_022_02584_4
crossref_primary_10_3390_cancers15041168
crossref_primary_10_3390_ijms25073780
crossref_primary_10_1186_s12935_024_03319_z
crossref_primary_10_1016_j_ejmech_2024_116702
crossref_primary_10_1007_s00232_024_00307_2
crossref_primary_10_1016_j_bios_2024_116347
crossref_primary_10_1186_s12929_021_00715_9
crossref_primary_10_1134_S0006297920100156
crossref_primary_10_1007_s42977_021_00072_6
crossref_primary_10_2147_IJN_S399322
crossref_primary_10_3390_nano13091447
crossref_primary_10_1007_s10238_023_01177_z
crossref_primary_10_1039_D4RA03060E
crossref_primary_10_1007_s10637_023_01338_7
crossref_primary_10_1007_s12672_024_00993_3
crossref_primary_10_1155_2022_9529114
crossref_primary_10_1016_j_radmp_2024_03_002
crossref_primary_10_1016_j_prp_2023_154917
crossref_primary_10_3892_mco_2023_2643
crossref_primary_10_34172_apb_2020_042
crossref_primary_10_1016_j_canlet_2020_04_008
crossref_primary_10_1021_acsanm_4c04925
crossref_primary_10_1186_s13071_020_04346_1
crossref_primary_10_1002_cncr_35096
crossref_primary_10_1007_s13258_023_01368_8
crossref_primary_10_1186_s40779_022_00401_3
crossref_primary_10_1016_j_jbc_2025_108304
crossref_primary_10_3389_fmolb_2023_1165781
crossref_primary_10_3390_cancers15030576
crossref_primary_10_1002_cai2_21
crossref_primary_10_1186_s13058_023_01694_5
crossref_primary_10_3389_fphar_2024_1446414
crossref_primary_10_1007_s10989_022_10443_9
crossref_primary_10_1016_j_ijbiomac_2020_06_130
crossref_primary_10_3892_or_2024_8849
crossref_primary_10_2174_1381612826666200811175513
crossref_primary_10_1016_j_compbiolchem_2024_108084
crossref_primary_10_26599_FSHW_2024_9250251
crossref_primary_10_1073_pnas_2421710122
crossref_primary_10_3390_cancers15174374
crossref_primary_10_1016_j_jfma_2025_03_003
crossref_primary_10_1016_j_bioorg_2021_105453
crossref_primary_10_1016_j_lfs_2020_118128
crossref_primary_10_3390_cells9071582
crossref_primary_10_1515_biol_2022_0535
crossref_primary_10_3389_fonc_2024_1366900
crossref_primary_10_62347_JWHA6355
Cites_doi 10.1038/s41416-018-0340-2
10.1200/JCO.2017.35.15_suppl.108
10.1158/0008-5472.CAN-03-2868
10.1038/onc.2009.337
10.1200/JCO.1997.15.7.2518
10.1158/1535-7163.MCT-17-0403
10.1007/s10549-011-1572-5
10.1073/pnas.1016569108
10.1038/nature01392
10.3322/caac.21208
10.1128/MCB.9.3.1165
10.1158/0008-5472.473.65.2
10.1200/JCO.1997.15.8.2894
10.1074/jbc.M403080200
10.1200/JCO.2011.35.6725
10.1200/JCO.2006.06.1440
10.4062/biomolther.2015.116
10.1073/pnas.1014835108
10.1038/sj.bjc.6602930
10.1056/NEJMoa1200690
10.1126/science.3798106
10.1016/j.imlet.2019.03.011
10.1007/s40259-018-0308-z
10.3389/fonc.2012.00062
10.1056/NEJMc0801440
10.1080/14712598.2019.1554052
10.4143/crt.2016.058
10.4161/cc.23274
10.1002/1097-0142(19940201)73:3<652::AID-CNCR2820730324>3.0.CO;2-4
10.1016/j.bcp.2011.11.011
10.1016/j.jchromb.2016.08.009
10.1158/1078-0432.CCR-17-3473
10.1016/j.ejca.2014.07.004
10.1158/0008-5472.CAN-08-4597
10.1093/jnci/djk134
10.1007/s10637-018-0649-y
10.1093/annonc/mdx002
10.1038/sj.onc.1205184
10.1200/jco.2008.26.15_suppl.1027
10.1172/JCI37964
10.1016/S0093-7754(01)90276-3
10.3390/membranes4030424
10.1073/pnas.0810571106
10.1056/NEJMoa1209124
10.1016/j.ccr.2009.03.020
10.1200/JCO.2009.26.7609
10.1038/bjc.2011.516
10.1186/s13058-015-0663-3
10.1158/0008-5472.CAN-05-1182
10.1007/s00280-011-1817-3
10.1038/ncomms2413
10.1200/JCO.2008.21.4437
10.1038/onc.2008.207
10.1038/s41416-018-0147-1
10.1200/JCO.2012.44.2806
10.1186/s13058-015-0624-x
10.1038/s41467-018-07608-w
10.1200/JCO.2002.20.3.719
10.1016/j.drudis.2007.10.007
10.1002/bit.26791
10.1016/j.ccr.2007.08.030
10.1016/S0092-8674(85)80050-7
10.1158/0008-5472.CAN-05-3555
10.1016/j.tips.2009.11.006
10.1038/s41598-018-22250-8
10.1093/annonc/mdy048.005
10.1080/19420862.2016.1204503
10.1016/j.lungcan.2018.10.019
10.1126/scitranslmed.aat1445
10.1200/JCO.1995.13.5.1129
10.1200/JCO.2007.11.6699
10.1038/sj.onc.1209685
10.1158/1078-0432.CCR-06-2837
10.1093/annonc/mdi059
10.1016/j.ygyno.2017.04.023
10.18632/oncotarget.10642
10.3390/cancers10100342
10.1007/s10549-013-2581-3
10.1002/cncr.11656
10.1038/bjc.2011.369
10.1200/jco.2009.27.15_suppl.1022
10.1093/annonc/12.suppl_1.S21
10.1200/JCO.2009.25.8707
10.1089/dna.2018.4427
10.1124/mol.114.095380
10.1007/s10549-012-2003-y
10.1093/annonc/mdg316
10.1073/pnas.0908801107
10.1038/74704
10.1038/onc.2013.308
10.4103/0973-1482.138195
10.1158/1078-0432.CCR-17-3250
10.26226/morressier.5afac509d0241f0023ccbf33
10.1016/j.drudis.2015.02.008
10.1200/jco.2007.25.18_suppl.1115
10.1016/j.ccr.2004.06.022
10.1038/35052073
10.1200/JCO.2009.23.7370
10.1038/ncponc0509
10.1038/sj.onc.1210478
10.1056/NEJMcibr043143
10.1016/j.molonc.2015.10.005
10.1038/onc.2015.58
10.1038/nrclinonc.2011.177
10.18632/oncotarget.13104
10.1038/sj.onc.1208478
10.1016/j.imlet.2019.03.004
10.1038/onc.2012.158
10.1016/j.ctrv.2013.09.002
10.1056/NEJMe1113641
10.1016/S0021-9258(18)52354-1
10.1038/bjc.2016.101
10.1016/j.ctrv.2018.04.016
10.1186/s40164-017-0091-4
ContentType Journal Article
Copyright 2019 Wiley Periodicals, Inc.
2020 Wiley Periodicals, Inc.
Copyright_xml – notice: 2019 Wiley Periodicals, Inc.
– notice: 2020 Wiley Periodicals, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
7X8
DOI 10.1002/jcp.29216
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Genetics Abstracts
MEDLINE

MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Biology
EISSN 1097-4652
EndPage 3156
ExternalDocumentID 31566722
10_1002_jcp_29216
JCP29216
Genre reviewArticle
Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
-DZ
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
9M8
A03
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDPE
ABEFU
ABEML
ABIJN
ABJNI
ABPPZ
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACNCT
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BQCPF
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
H~9
IH2
IX1
J0M
JPC
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M56
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MVM
MXFUL
MXSTM
N04
N05
N9A
NEJ
NF~
NNB
O66
O9-
OHT
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RWR
RX1
RYL
S10
SAMSI
SUPJJ
SV3
TN5
TWZ
UB1
UPT
V2E
V8K
VQP
W8V
W99
WBKPD
WH7
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WXSBR
WYB
WYISQ
X7M
XG1
XJT
XOL
XPP
XSW
XV2
Y6R
YQT
YZZ
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
ADXHL
AETEA
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c4196-3d84a632ae0f91908c96adde0e8c99865c3432a7c2bb1b52ed5cf836769e6b593
IEDL.DBID DR2
ISSN 0021-9541
1097-4652
IngestDate Fri Jul 11 02:13:50 EDT 2025
Fri Jul 25 10:09:25 EDT 2025
Mon Jul 21 06:08:36 EDT 2025
Thu Apr 24 22:56:44 EDT 2025
Tue Jul 01 01:32:05 EDT 2025
Wed Jan 22 16:35:15 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords trastuzumab
HER2 positive
breast cancer
drug resistance
Language English
License 2019 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4196-3d84a632ae0f91908c96adde0e8c99865c3432a7c2bb1b52ed5cf836769e6b593
Notes Afshin Derakhshani and Zohreh Rezaei contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-8642-6795
0000-0002-3243-233X
PMID 31566722
PQID 2333563010
PQPubID 1006363
PageCount 15
ParticipantIDs proquest_miscellaneous_2299457089
proquest_journals_2333563010
pubmed_primary_31566722
crossref_primary_10_1002_jcp_29216
crossref_citationtrail_10_1002_jcp_29216
wiley_primary_10_1002_jcp_29216_JCP29216
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2020
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 04
  year: 2020
  text: April 2020
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Journal of cellular physiology
PublicationTitleAlternate J Cell Physiol
PublicationYear 2020
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References Louie M. C. (e_1_2_10_1_62_1) 2017; 7
e_1_2_10_1_124_1
e_1_2_10_1_101_1
e_1_2_10_1_29_1
e_1_2_10_1_120_1
Pietras R. J. (e_1_2_10_1_85_1) 1999; 59
e_1_2_10_1_25_1
e_1_2_10_1_48_1
e_1_2_10_1_67_1
e_1_2_10_1_109_1
e_1_2_10_1_44_1
e_1_2_10_1_63_1
e_1_2_10_1_86_1
Klapper L. N. (e_1_2_10_1_47_1) 2000; 60
e_1_2_10_1_128_1
e_1_2_10_1_40_1
e_1_2_10_1_82_1
e_1_2_10_1_116_1
e_1_2_10_1_7_1
e_1_2_10_1_112_1
e_1_2_10_1_18_1
e_1_2_10_1_131_1
e_1_2_10_1_14_1
e_1_2_10_1_37_1
e_1_2_10_1_56_1
e_1_2_10_1_79_1
Colomer R. (e_1_2_10_1_21_1) 2000; 6
e_1_2_10_1_52_1
e_1_2_10_1_98_1
e_1_2_10_1_10_1
e_1_2_10_1_33_1
e_1_2_10_1_3_1
e_1_2_10_1_75_1
Khattar M. (e_1_2_10_1_45_1) 2018; 200
e_1_2_10_1_94_1
e_1_2_10_1_90_1
Hayes D. F. (e_1_2_10_1_38_1) 2001; 7
e_1_2_10_1_104_1
e_1_2_10_1_127_1
Lin Y. Z. (e_1_2_10_1_60_1) 1991; 6
Molina M. A. (e_1_2_10_1_71_1) 2001; 61
e_1_2_10_1_100_1
e_1_2_10_1_123_1
e_1_2_10_1_49_1
e_1_2_10_1_26_1
e_1_2_10_1_68_1
e_1_2_10_1_108_1
e_1_2_10_1_41_1
e_1_2_10_1_87_1
Nagy P. (e_1_2_10_1_74_1) 2005; 65
e_1_2_10_1_22_1
e_1_2_10_1_64_1
e_1_2_10_1_83_1
Sharma A. (e_1_2_10_1_105_1) 2010; 5
Sperinde J. (e_1_2_10_1_110_1) 2016; 76
e_1_2_10_1_115_1
e_1_2_10_1_8_1
e_1_2_10_1_111_1
e_1_2_10_1_19_1
e_1_2_10_1_34_1
e_1_2_10_1_15_1
e_1_2_10_1_57_1
e_1_2_10_1_53_1
e_1_2_10_1_76_1
e_1_2_10_1_99_1
e_1_2_10_1_30_1
e_1_2_10_1_119_1
e_1_2_10_1_4_1
e_1_2_10_1_11_1
e_1_2_10_1_72_1
e_1_2_10_1_95_1
e_1_2_10_1_91_1
e_1_2_10_1_126_1
e_1_2_10_1_103_1
e_1_2_10_1_27_1
e_1_2_10_1_122_1
e_1_2_10_1_23_1
e_1_2_10_1_46_1
e_1_2_10_1_69_1
Codony‐Servat J. (e_1_2_10_1_20_1) 1999; 59
e_1_2_10_1_42_1
e_1_2_10_1_65_1
e_1_2_10_1_88_1
e_1_2_10_1_107_1
e_1_2_10_1_61_1
e_1_2_10_1_84_1
e_1_2_10_1_80_1
e_1_2_10_1_9_1
e_1_2_10_1_114_1
e_1_2_10_1_39_1
Zhang S. (e_1_2_10_1_130_1) 2011; 17
e_1_2_10_1_12_1
e_1_2_10_1_35_1
e_1_2_10_1_58_1
e_1_2_10_1_31_1
e_1_2_10_1_5_1
e_1_2_10_1_77_1
e_1_2_10_1_118_1
e_1_2_10_1_54_1
e_1_2_10_1_96_1
e_1_2_10_1_73_1
Christianson T. A. (e_1_2_10_1_16_1) 1998; 58
e_1_2_10_1_50_1
e_1_2_10_1_92_1
e_1_2_10_1_102_1
e_1_2_10_1_125_1
e_1_2_10_1_28_1
e_1_2_10_1_121_1
e_1_2_10_1_24_1
e_1_2_10_1_66_1
e_1_2_10_1_106_1
e_1_2_10_1_129_1
e_1_2_10_1_43_1
e_1_2_10_1_81_1
e_1_2_10_1_113_1
e_1_2_10_1_17_1
Pupa S. M. (e_1_2_10_1_89_1) 1993; 8
e_1_2_10_1_2_1
e_1_2_10_1_13_1
e_1_2_10_1_59_1
e_1_2_10_1_78_1
e_1_2_10_1_36_1
e_1_2_10_1_6_1
e_1_2_10_1_55_1
e_1_2_10_1_97_1
e_1_2_10_1_32_1
e_1_2_10_1_117_1
e_1_2_10_1_51_1
e_1_2_10_1_70_1
e_1_2_10_1_93_1
References_xml – ident: e_1_2_10_1_83_1
  doi: 10.1038/s41416-018-0340-2
– ident: e_1_2_10_1_27_1
  doi: 10.1200/JCO.2017.35.15_suppl.108
– ident: e_1_2_10_1_90_1
  doi: 10.1158/0008-5472.CAN-03-2868
– ident: e_1_2_10_1_14_1
  doi: 10.1038/onc.2009.337
– volume: 59
  start-page: 1347
  issue: 6
  year: 1999
  ident: e_1_2_10_1_85_1
  article-title: Monoclonal antibody to HER‐2/neureceptor modulates repair of radiation‐induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
  publication-title: Cancer Research
– ident: e_1_2_10_1_126_1
  doi: 10.1200/JCO.1997.15.7.2518
– ident: e_1_2_10_1_114_1
  doi: 10.1158/1535-7163.MCT-17-0403
– ident: e_1_2_10_1_92_1
  doi: 10.1007/s10549-011-1572-5
– volume: 7
  start-page: 2703
  issue: 9
  year: 2001
  ident: e_1_2_10_1_38_1
  article-title: Circulating HER‐2/erbB‐2/c‐neu (HER‐2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662
  publication-title: Clinical Cancer Research
– ident: e_1_2_10_1_113_1
  doi: 10.1073/pnas.1016569108
– volume: 7
  start-page: 1617
  issue: 8
  year: 2017
  ident: e_1_2_10_1_62_1
  article-title: Steroid hormone receptors as prognostic markers in breast cancer
  publication-title: American Journal of Cancer Research
– ident: e_1_2_10_1_15_1
  doi: 10.1038/nature01392
– ident: e_1_2_10_1_106_1
  doi: 10.3322/caac.21208
– ident: e_1_2_10_1_39_1
  doi: 10.1128/MCB.9.3.1165
– volume: 65
  start-page: 473
  issue: 2
  year: 2005
  ident: e_1_2_10_1_74_1
  article-title: Decreased accessibility and lack of activation of ErbB2 in JIMT‐1, a herceptin‐resistant, MUC4‐expressing breast cancer cell line
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.473.65.2
– ident: e_1_2_10_1_87_1
  doi: 10.1200/JCO.1997.15.8.2894
– volume: 8
  start-page: 2917
  issue: 11
  year: 1993
  ident: e_1_2_10_1_89_1
  article-title: The extracellular domain of the c‐erbB‐2 oncoprotein is released from tumor cells by proteolytic cleavage
  publication-title: Oncogene
– ident: e_1_2_10_1_57_1
  doi: 10.1074/jbc.M403080200
– volume: 6
  start-page: 639
  issue: 4
  year: 1991
  ident: e_1_2_10_1_60_1
  article-title: A soluble protein related to the HER‐2 proto‐oncogene product is released from human breast carcinoma cells
  publication-title: Oncogene
– ident: e_1_2_10_1_10_1
  doi: 10.1200/JCO.2011.35.6725
– ident: e_1_2_10_1_34_1
  doi: 10.1200/JCO.2006.06.1440
– ident: e_1_2_10_1_46_1
  doi: 10.4062/biomolther.2015.116
– ident: e_1_2_10_1_99_1
  doi: 10.1073/pnas.1014835108
– ident: e_1_2_10_1_3_1
  doi: 10.1038/sj.bjc.6602930
– ident: e_1_2_10_1_116_1
  doi: 10.1056/NEJMoa1200690
– ident: e_1_2_10_1_107_1
  doi: 10.1126/science.3798106
– ident: e_1_2_10_1_26_1
  doi: 10.1016/j.imlet.2019.03.011
– ident: e_1_2_10_1_79_1
  doi: 10.1007/s40259-018-0308-z
– ident: e_1_2_10_1_18_1
  doi: 10.3389/fonc.2012.00062
– ident: e_1_2_10_1_80_1
  doi: 10.1056/NEJMc0801440
– ident: e_1_2_10_1_41_1
  doi: 10.1080/14712598.2019.1554052
– ident: e_1_2_10_1_37_1
  doi: 10.4143/crt.2016.058
– ident: e_1_2_10_1_66_1
  doi: 10.4161/cc.23274
– ident: e_1_2_10_1_40_1
  doi: 10.1002/1097-0142(19940201)73:3<652::AID-CNCR2820730324>3.0.CO;2-4
– ident: e_1_2_10_1_64_1
  doi: 10.1016/j.bcp.2011.11.011
– ident: e_1_2_10_1_131_1
  doi: 10.1016/j.jchromb.2016.08.009
– ident: e_1_2_10_1_31_1
  doi: 10.1158/1078-0432.CCR-17-3473
– ident: e_1_2_10_1_33_1
  doi: 10.1016/j.ejca.2014.07.004
– ident: e_1_2_10_1_101_1
  doi: 10.1158/0008-5472.CAN-08-4597
– ident: e_1_2_10_1_100_1
  doi: 10.1093/jnci/djk134
– ident: e_1_2_10_1_13_1
  doi: 10.1007/s10637-018-0649-y
– ident: e_1_2_10_1_77_1
  doi: 10.1093/annonc/mdx002
– ident: e_1_2_10_1_6_1
  doi: 10.1038/sj.onc.1205184
– ident: e_1_2_10_1_70_1
  doi: 10.1200/jco.2008.26.15_suppl.1027
– ident: e_1_2_10_1_65_1
  doi: 10.1172/JCI37964
– ident: e_1_2_10_1_5_1
  doi: 10.1016/S0093-7754(01)90276-3
– ident: e_1_2_10_1_8_1
  doi: 10.3390/membranes4030424
– ident: e_1_2_10_1_29_1
  doi: 10.1073/pnas.0810571106
– volume: 5
  start-page: 21
  issue: 2
  year: 2010
  ident: e_1_2_10_1_105_1
  article-title: Neratinib, an irreversible erbB receptor tyrosine kinase inhibitor, in patients with advanced erbB2‐positive breast cancer
  publication-title: Advances in Oncology
– ident: e_1_2_10_1_121_1
  doi: 10.1056/NEJMoa1209124
– ident: e_1_2_10_1_43_1
  doi: 10.1016/j.ccr.2009.03.020
– volume: 59
  start-page: 1196
  issue: 6
  year: 1999
  ident: e_1_2_10_1_20_1
  article-title: Cleavage of the HER2 ectodomain is a pervanadate‐activable process that is inhibited by the tissue inhibitor of metalloproteases‐1 in breast cancer cells
  publication-title: Cancer Research
– ident: e_1_2_10_1_11_1
  doi: 10.1200/JCO.2009.26.7609
– ident: e_1_2_10_1_118_1
  doi: 10.1038/bjc.2011.516
– ident: e_1_2_10_1_23_1
  doi: 10.1186/s13058-015-0663-3
– ident: e_1_2_10_1_50_1
  doi: 10.1158/0008-5472.CAN-05-1182
– ident: e_1_2_10_1_35_1
  doi: 10.1007/s00280-011-1817-3
– volume: 17
  start-page: 461
  issue: 4
  year: 2011
  ident: e_1_2_10_1_130_1
  article-title: Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
  publication-title: Nature Medicine (New York, NY, United States)
– ident: e_1_2_10_1_2_1
  doi: 10.1038/ncomms2413
– ident: e_1_2_10_1_9_1
  doi: 10.1200/JCO.2008.21.4437
– ident: e_1_2_10_1_52_1
  doi: 10.1038/onc.2008.207
– ident: e_1_2_10_1_55_1
  doi: 10.1038/s41416-018-0147-1
– ident: e_1_2_10_1_104_1
  doi: 10.1200/JCO.2012.44.2806
– ident: e_1_2_10_1_44_1
  doi: 10.1186/s13058-015-0624-x
– ident: e_1_2_10_1_84_1
  doi: 10.1038/s41467-018-07608-w
– volume: 61
  start-page: 4744
  issue: 12
  year: 2001
  ident: e_1_2_10_1_71_1
  article-title: Trastuzumab (herceptin), a humanized anti‐Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
  publication-title: Cancer Research
– ident: e_1_2_10_1_122_1
  doi: 10.1200/JCO.2002.20.3.719
– ident: e_1_2_10_1_109_1
  doi: 10.1016/j.drudis.2007.10.007
– ident: e_1_2_10_1_24_1
  doi: 10.1002/bit.26791
– ident: e_1_2_10_1_7_1
  doi: 10.1016/j.ccr.2007.08.030
– ident: e_1_2_10_1_28_1
  doi: 10.1016/S0092-8674(85)80050-7
– ident: e_1_2_10_1_42_1
  doi: 10.1158/0008-5472.CAN-05-3555
– ident: e_1_2_10_1_88_1
  doi: 10.1016/j.tips.2009.11.006
– ident: e_1_2_10_1_94_1
– ident: e_1_2_10_1_17_1
  doi: 10.1038/s41598-018-22250-8
– ident: e_1_2_10_1_82_1
  doi: 10.1093/annonc/mdy048.005
– ident: e_1_2_10_1_117_1
  doi: 10.1080/19420862.2016.1204503
– ident: e_1_2_10_1_49_1
  doi: 10.1016/j.lungcan.2018.10.019
– ident: e_1_2_10_1_96_1
  doi: 10.1126/scitranslmed.aat1445
– ident: e_1_2_10_1_58_1
  doi: 10.1200/JCO.1995.13.5.1129
– ident: e_1_2_10_1_102_1
  doi: 10.1200/JCO.2007.11.6699
– ident: e_1_2_10_1_124_1
  doi: 10.1038/sj.onc.1209685
– ident: e_1_2_10_1_63_1
  doi: 10.1158/1078-0432.CCR-06-2837
– ident: e_1_2_10_1_32_1
  doi: 10.1093/annonc/mdi059
– ident: e_1_2_10_1_67_1
  doi: 10.1016/j.ygyno.2017.04.023
– ident: e_1_2_10_1_97_1
  doi: 10.18632/oncotarget.10642
– ident: e_1_2_10_1_76_1
  doi: 10.3390/cancers10100342
– ident: e_1_2_10_1_72_1
  doi: 10.1007/s10549-013-2581-3
– ident: e_1_2_10_1_48_1
  doi: 10.1002/cncr.11656
– ident: e_1_2_10_1_115_1
  doi: 10.1038/bjc.2011.369
– ident: e_1_2_10_1_22_1
  doi: 10.1200/jco.2009.27.15_suppl.1022
– ident: e_1_2_10_1_56_1
  doi: 10.1093/annonc/12.suppl_1.S21
– volume: 58
  start-page: 5123
  issue: 22
  year: 1998
  ident: e_1_2_10_1_16_1
  article-title: NH2‐terminally truncated HER‐2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
  publication-title: Cancer Research
– ident: e_1_2_10_1_12_1
  doi: 10.1200/JCO.2009.25.8707
– ident: e_1_2_10_1_95_1
  doi: 10.1089/dna.2018.4427
– ident: e_1_2_10_1_98_1
  doi: 10.1124/mol.114.095380
– ident: e_1_2_10_1_59_1
  doi: 10.1007/s10549-012-2003-y
– ident: e_1_2_10_1_30_1
  doi: 10.1093/annonc/mdg316
– ident: e_1_2_10_1_112_1
  doi: 10.1073/pnas.0908801107
– ident: e_1_2_10_1_19_1
  doi: 10.1038/74704
– ident: e_1_2_10_1_91_1
  doi: 10.1038/onc.2013.308
– ident: e_1_2_10_1_125_1
  doi: 10.4103/0973-1482.138195
– volume: 76
  start-page: Suppl
  issue: 4
  year: 2016
  ident: e_1_2_10_1_110_1
  article-title: Abstract P3‐07‐09: Quantitative p95HER2 protein expression is predictive of trastuzumab response in HER2‐positive metastatic breast cancer
  publication-title: Cancer Research
– ident: e_1_2_10_1_111_1
  doi: 10.1158/1078-0432.CCR-17-3250
– ident: e_1_2_10_1_93_1
  doi: 10.26226/morressier.5afac509d0241f0023ccbf33
– ident: e_1_2_10_1_51_1
  doi: 10.1016/j.drudis.2015.02.008
– ident: e_1_2_10_1_68_1
  doi: 10.1200/jco.2007.25.18_suppl.1115
– ident: e_1_2_10_1_73_1
  doi: 10.1016/j.ccr.2004.06.022
– ident: e_1_2_10_1_127_1
  doi: 10.1038/35052073
– ident: e_1_2_10_1_25_1
  doi: 10.1200/JCO.2009.23.7370
– ident: e_1_2_10_1_108_1
– ident: e_1_2_10_1_75_1
  doi: 10.1038/ncponc0509
– ident: e_1_2_10_1_69_1
  doi: 10.1038/sj.onc.1210478
– ident: e_1_2_10_1_81_1
  doi: 10.1056/NEJMcibr043143
– ident: e_1_2_10_1_78_1
  doi: 10.1016/j.molonc.2015.10.005
– ident: e_1_2_10_1_61_1
  doi: 10.1038/onc.2015.58
– volume: 200
  start-page: 122
  issue: 1
  year: 2018
  ident: e_1_2_10_1_45_1
  article-title: Synergy of an anti‐HER2 ADC TAK‐522 (XMT‐1522) in combination with anti‐PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2
  publication-title: The Journal of Immunology
– ident: e_1_2_10_1_4_1
  doi: 10.1038/nrclinonc.2011.177
– ident: e_1_2_10_1_123_1
  doi: 10.18632/oncotarget.13104
– ident: e_1_2_10_1_120_1
  doi: 10.1038/sj.onc.1208478
– ident: e_1_2_10_1_119_1
  doi: 10.1016/j.imlet.2019.03.004
– ident: e_1_2_10_1_53_1
  doi: 10.1038/onc.2012.158
– ident: e_1_2_10_1_54_1
  doi: 10.1016/j.ctrv.2013.09.002
– volume: 6
  start-page: 2356
  issue: 6
  year: 2000
  ident: e_1_2_10_1_21_1
  article-title: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
  publication-title: Clinical Cancer Research
– ident: e_1_2_10_1_36_1
  doi: 10.1056/NEJMe1113641
– volume: 60
  start-page: 3384
  issue: 13
  year: 2000
  ident: e_1_2_10_1_47_1
  article-title: Tumor‐inhibitory antibodies to HER‐2/ErbB‐2 may act by recruiting c‐Cbl and enhancing ubiquitination of HER‐2
  publication-title: Cancer Research
– ident: e_1_2_10_1_129_1
  doi: 10.1016/S0021-9258(18)52354-1
– ident: e_1_2_10_1_103_1
  doi: 10.1038/bjc.2016.101
– ident: e_1_2_10_1_86_1
  doi: 10.1016/j.ctrv.2018.04.016
– ident: e_1_2_10_1_128_1
  doi: 10.1186/s40164-017-0091-4
SSID ssj0009933
Score 2.5886302
SecondaryResourceType review_article
Snippet Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis....
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) comprises around 20-30% of all BC subtypes and is correlated with poor prognosis....
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3142
SubjectTerms Antineoplastic Agents - pharmacology
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Combination therapy
drug resistance
Drug Resistance, Neoplasm - drug effects
Epidermal growth factor
ErbB-2 protein
Growth factors
HER2 positive
Humans
Immunotherapy
Lapatinib - therapeutic use
Monoclonal antibodies
Receptor, ErbB-2 - drug effects
Targeted cancer therapy
Trastuzumab
Trastuzumab - therapeutic use
Title Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.29216
https://www.ncbi.nlm.nih.gov/pubmed/31566722
https://www.proquest.com/docview/2333563010
https://www.proquest.com/docview/2299457089
Volume 235
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CoNBLH0kf26RFLaX04o1XkmWJnkJIWHJoS2ggh4CRtNrSR5ywawc2p_6E_sb-ks5ItkP6gNKbwLL80IznG_nTNwAvZ44jCNUhk6XXmZROZVY7kymN4WVmCjSRSJB9q6bH8vCkOFmDN_1emKQPMSy4kWfE7zU5uHXLnWvR0M_-YswNn5DcNnG1CBAdXUtHma6MfKQgFHLSqwrlfGc482Ys-g1g3sSrMeAc3IXT_lYTz-TLuG3c2F_9ouL4n89yD-50QJTtJsu5D2uh3oDN3RqT8LMVe8UiNTSuuW_ArVSxcrUJp-_Q9HF0DHisWdhl0161Z9YxTNoJiKIFsU81m-4f8R_fvidC2GVgjpjvDfN0fMGIav-R4SCYlEe7YGkT2OoBHB_sf9ibZl2BhsxL9NxMzLS0SnAb8rlBZKG9UfS9zAO2jFaFp22rtvTcuYkreJgVfq5JI84E5QojHsJ6fV6Hx8Ck9c5bjJx2XpIEocMhlSid0ggBtfAjeN1PVeU79XIqovG1SrrLvMJ3WMV3OIIXQ9eLJNnxp07b_XxXndcuKy6EIL20ST6C58Nh9Df6iWLrcN5iH4zfsihzbUbwKNnJcBVByXDJOd5snO2_X7463HsfG0_-vesW3OaU7Efa0DasN4s2PEVE1Lhn0fR_Ah6WBvM
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgQXHi2PhQIGIcQl26ydOLbEpSqtllIKqlqpB1Bke72IR9NqmyBtT_wEfiO_hBk7SVUeEuJmyY6d2DOeGefzNwBPJpajE6p8khVOJVlmZWKU1YlUaF4mOkcRCQDZHTnez7YO8oMFeN7dhYn8EP2BG2lG2K9JwelAevWMNfSTOx5yzUfyAlykjN7EnP9i94w8SreJ5AMIIc9GHa9Qylf7R89bo99czPMeazA5m9fgffeyEWnyedjUduhOf-Fx_N-vuQ5XW1-UrUXhuQELvlqC5bUK4_DDOXvKAjo0HLsvwaWYtHK-DO_eoPRj92jzWD0zJ3Vz2hwayzBuJ18UhYh9rNh4Y5f_-PY9YsK-emYJ_F4zR_UzRmj7Dww7wbg8iAaL98DmN2F_c2NvfZy0ORoSl6HyJmKiMiMFNz6danQulNOStszUY0krmTu6uWoKx60d2Zz7Se6mimjitJc21-IWLFZHlb8DLDPOOoPG00wLYiG02KUUhZUKvUAl3ACedWtVupbAnPJofCkj9TIvcQ7LMIcDeNw3PY6sHX9qtNIteNkq7knJhRBEmTZKB_Cor0aVo_8opvJHDbZBE57lRar0AG5HQelHERQPF5zjy4bl_vvw5db621C4--9NH8Ll8d7r7XL75c6re3CFU-wfUEQrsFjPGn8fHaTaPgh68BOAdAsP
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIhAXHi2FhQIGIcQl26ztOLY4VW1XS0GlqqjUQ6XIdryIR9PVNkHanvgJ_EZ-CWM7SVUeEuJmyY6d2DOeGefzNwDPS0PRCZUu4bmVCedGJFoalQiJ5qVUGYpIAMjuickh3z3KjpbgVXcXJvJD9AduXjPCfu0VfFZONy5IQz_Z2ZAqOhJX4CoXqfJ5G7YPLrijVJtHPmAQMj7qaIVSutE_etkY_eZhXnZYg8UZ34Lj7l0j0OTzsKnN0J7_QuP4nx9zG262nijZjKJzB5ZctQKrmxVG4ScL8oIEbGg4dF-BazFl5WIVjt-h7GPvaPFIPddndXPenGhDMGr3niiKEPlYkcnOAf3x7XtEhH11xHjoe02sr58Tj7X_QLATjMqDYJB4C2xxFw7HO--3JkmboSGxHFU3YaXkWjCqXTpV6FpIq4TfMFOHJSVFZv29VZ1baszIZNSVmZ1KTxKnnDCZYmuwXJ1W7j4Qrq2xGk2nnuaeg9Bgl4LlRkj0ASWzA3jZLVVhW_pyn0XjSxGJl2mBc1iEORzAs77pLHJ2_KnRerfeRau2ZwVljHnCtFE6gKd9NSqc_4uiK3faYBs04DzLU6kGcC_KST8K89FwTim-bFjtvw9f7G7th8KDf2_6BK7vb4-Lt6_33jyEG9QH_gFCtA7L9bxxj9A7qs3joAU_AV0SCb4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overcoming+trastuzumab+resistance+in+HER2-positive+breast+cancer+using+combination+therapy&rft.jtitle=Journal+of+cellular+physiology&rft.au=Derakhshani%2C+Afshin&rft.au=Rezaei%2C+Zohreh&rft.au=Safarpour%2C+Hossein&rft.au=Sabri%2C+Morteza&rft.date=2020-04-01&rft.eissn=1097-4652&rft.volume=235&rft.issue=4&rft.spage=3142&rft_id=info:doi/10.1002%2Fjcp.29216&rft_id=info%3Apmid%2F31566722&rft.externalDocID=31566722
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon